Inventor · disambiguated record
Lewis C. Cantley
Also filed as: CANTLEY LEWIS · CANTLEY LEWIS C
17 granted patents·25 pending applications·192 citations·filing 1994–2023
93Inventor score
Files withDANA FARBER CANCER INST INC7CANTLEY LEWIS C6UNIV CORNELL6BETH ISRAEL HOSPITAL4MAX PLANCK GESELLSCHAFT2
Top patents by PatentIndex Score
42 records- 0190US8883438B2Method for diagnosing cell proliferation disorders having a neoactive mutation at residue 97 of isocitrate dehydrogenase 1CANTLEY LEWIS C·Filed 2012·Granted Nov 11, 2014·18 cites·12 claims
- 0287US8552050B2Activators of pyruvate kinase M2 and methods of treating diseaseCANTLEY LEWIS C·Filed 2008·Granted Oct 8, 2013·20 cites·4 claims
- 0386US5532167ASubstrate specificity of protein kinasesBETH ISRAEL HOSPITAL·Filed 1994·Granted Jul 2, 1996·75 cites·32 claims
- 0485US8877791B2Inhibitors of pyruvate kinase and methods of treating diseaseCANTLEY LEWIS·Filed 2007·Granted Nov 4, 2014·19 cites·1 claims
- 0582US9745631B2Methods for diagnosing and treating oncogenic kras-associated cancerDANA FARBER CANCER INST INC·Filed 2012·Granted Aug 29, 2017·4 cites·12 claims
- 0682US8715665B2Methods for treating cancer resistant to ErbB therapeuticsJANNE PASI A·Filed 2008·Granted May 6, 2014·10 cites·12 claims
- 0778US6462173B1Inhibitors of phosphoserine and phosphothreonine-proline-specific isomerasesMAX PLANCK GESELLSCHAFT·Filed 1997·Granted Oct 8, 2002·27 cites·19 claims
- 0877US10837015B2Targeting the glutamine to pyruvate pathway for treatment of oncogenic Kras-associated cancerDANA FARBER CANCER INST INC·Filed 2018·Granted Nov 17, 2020·1 cites·29 claims
- 0970US2024165122A1Combination therapy for pi3k-associated disease or disorderUNIV COLUMBIA·Filed 2023·Application pending·0 cites
- 1067US12324807B2Combination therapy for PI3K-associated disease or disorderUNIV CORNELL·Filed 2019·Granted Jun 10, 2025·0 cites·40 claims
- 1166US10138479B2Targeting the glutamine to pyruvate pathway for treatment of oncogenic Kras-associated cancerDANA FARBER CANCER INST INC·Filed 2013·Granted Nov 27, 2018·1 cites·29 claims
- 1264US9493813B2Modulation of phosphatidylinositol-5-phosphate-4-kinase activityEMERLING BROOKE·Filed 2012·Granted Nov 15, 2016·1 cites·24 claims
- 1364US2024110246A1Targeting chromosomal instability and downstream cytosolic dna signaling for cancer treatmentUNIV CORNELL·Filed 2023·Application pending·0 cites
- 1463US6004757ASubstrate specificity of a protein kinasesBETH ISRAEL HOSPITAL·Filed 1995·Granted Dec 21, 1999·15 cites·6 claims
- 1562US9119858B2Compositions and methods for treating or preventing anthracycline induced cardiotoxicityGENESYS RES INST·Filed 2013·Granted Sep 1, 2015·1 cites·9 claims
- 1661US2025134888A1Inhibitors of malic enzyme 1UNIV CORNELL·Filed 2023·Application pending·0 cites
- 1760US11008620B2Methods for treating cancer resistant to ErbB therapeuticsDANA FARBER CANCER INST INC·Filed 2015·Granted May 18, 2021·0 cites·20 claims
- 1858US2024167041A1Loss of lipid kinase pi5p4k gamma restricts tumor growthCANTLEY LEWIS C·Filed 2022·Application pending·0 cites
- 1957US11821042B2Targeting chromosomal instability and downstream cytosolic DNA signaling for cancer treatmentUNIV CORNELL·Filed 2018·Granted Nov 21, 2023·0 cites·15 claims
- 2056US2024277852A1Inhibitors and degraders of pip4k proteinDANA FARBER CANCER INST INC·Filed 2022·Application pending·0 cites
- 2155US2010030543A1Products and processes for modulating peptide-peptide binding domain interactionsYAFFE MICHAEL B·Filed 2008·Application pending·0 cites
- 2255US2024245786A1Small molecule degraders of phosphatidylinositol-5-phosphate 4-kinase type 2 and uses thereofDANA FARBER CANCER INST INC·Filed 2021·Application pending·0 cites
- 2355US2003109423A1Inhibitors of phosphoserine and phosphothreonine-proline-specific isomerasesMAX PLANCK GESELLSCHAFT·Filed 2002·Application pending·0 cites
- 2455US2014296100A1Methods for treating cancer resistant to erbb therapeuticsDANA FARBER CANCER INST INC·Filed 2014·Application pending·0 cites
- 2551US2022168402A1PIP4Ks SUPPRESS INSULIN SIGNALING AND ENHANCE IMMUNE FUNCTION THROUGH A CATALYTIC-INDEPENDENT MECHANISMUNIV CORNELL·Filed 2020·Application pending·0 cites
- 2650US2004028683A1Modulators of p85 expressionJOSLIN DIABETES CT INC A MASSA·Filed 2003·Application pending·0 cites
- 2749US2005196808A1Products and processes for modulating peptide-peptide binding domain interactionsFiled 2003·Application pending·0 cites
- 2849US2008194019A1Tumor Suppressor Lkb1 Kinase Directly Activates Amp-Activated KinaseBETH ISRAEL HOSPITAL·Filed 2004·Application pending·0 cites
- 2948US2011104713A1Products and processes for modulating peptide-peptide binding domain interactionsYAFFE MICHAEL B·Filed 2010·Application pending·0 cites
- 3047US12371507B2CDCP1 antibodies and antibody drug conjugatesBETH ISRAEL DEACONESS MEDICAL CT INC·Filed 2019·Granted Jul 29, 2025·0 cites·8 claims
- 3147US2010311807A1Methods for identifying diabetes and obesity therapeuticsUNIV WASHINGTON·Filed 2008·Application pending·0 cites
- 3246US2009324489A1Wortmannin conjugates and uses thereofYUAN HUSHAN·Filed 2006·Application pending·0 cites
- 3344US2022400732A1Anti-fructose therapy for colorectal and small intestine cancersUNIV CORNELL·Filed 2020·Application pending·0 cites
- 3443US2014235630A1Compositions and methods for the treatment of proliferative diseasesBETH ISRAEL HOSPITAL·Filed 2012·Application pending·0 cites
- 3543US2012122991A1Method for treating cancer by increasing amp-activated kinase activityCANTLEY LEWIS C·Filed 2012·Application pending·0 cites
- 3641US2002192711A1Methods for identifying ligands of G-Protein-Coupled receptorsFiled 2002·Application pending·0 cites
- 3741US2013203618A1Methods and compositions for the diagnosis and treatment of cellular proliferative disordersCANTLEY LEWIS C·Filed 2011·Application pending·0 cites
- 3840US10494365B2Small molecule inhibitor of 3-phosphoglycerate dehydrogenase and uses thereofSCRIPPS RESEARCH INST·Filed 2016·Granted Dec 3, 2019·0 cites·21 claims
- 3940US2002051786A1Modulators of p85 expressionFiled 2001·Application pending·0 cites
- 4038US2006089320A1Modulation of type IIß phosphoinositide phosphate kinaseCANTLEY LEWIS C·Filed 2003·Application pending·0 cites
- 4134US2003148377A1Binding compounds and methods for identifying binding compoundsFiled 2001·Application pending·0 cites
- 4224US2002068301A1Cyclic peptide libraries and methods of use thereof to identify binding motifsFiled 1997·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Lewis C. Cantley files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →